Search results for " type 2"

showing 10 items of 761 documents

Is Myeloperoxidase a Key Component in the ROS-Induced Vascular Damage Related to Nephropathy in Type 2 Diabetes?

2013

AbstractIt is still unclear whether microvascular complications of type 2 diabetes correlate with leukocyte-endothelium interactions and/or myeloperoxidase (MPO) levels. In the present study, we found that serum levels of glucose, the rate of ROS and MPO concentration were higher in type 2 diabetic patients. Patients with nephropathy (39.6%) presented higher MPO levels that correlate positively with the albumin/creatinine ratio (r=0.59, p<0.05). In addition, nephropatic patients showed increased leukocyte-endothelium interactions due to an undermining of polymorphonuclear leukocytes (PMN) rolling velocity and increased rolling flux and adhesion, which was accompanied by a rise in levels of …

medicine.medical_specialtyPhysiologyClinical BiochemistryType 2 diabetesmedicine.disease_causeBiochemistryNephropathyProinflammatory cytokinechemistry.chemical_compoundInternal medicinemedicineCell AdhesionHuman Umbilical Vein Endothelial CellsLeukocytesHumansNews & ViewsDiabetic NephropathiesCell adhesionMolecular BiologyCells CulturedGeneral Environmental SciencePeroxidaseCreatininebiologyCell adhesion moleculeCell BiologyMiddle Agedmedicine.diseaseEndocrinologychemistryDiabetes Mellitus Type 2Myeloperoxidasebiology.proteinGeneral Earth and Planetary SciencesCytokinesReactive Oxygen SpeciesCell Adhesion MoleculesOxidative stress
researchProduct

Crataegus laevigata decreases neutrophil elastase and has hypolipidemic effect: a randomized, double-blind, placebo-controlled trial.

2011

Crataegus laevigata is a medicinal plant most commonly used for the treatment of heart failure and psychosomatic disorders. Based on previous experimental findings, this double-blind placebo-controlled study was aimed at finding beneficial effects of C. laevigata on biomarkers of coronary heart disease (CHD). The study included 49 diabetic subjects with chronic CHD who were randomly assigned to the treatment for 6 months with either a micronized flower and leaf preparation of C. laevigata (400 mg three times a day) or a matching placebo. Blood cell count, lipid profile, C-reactive protein, neutrophil elastase (NE) and malondialdehyde were analyzed in plasma at baseline, at one month and six…

medicine.medical_specialtyPlacebo-controlled studyPharmaceutical ScienceCoronary DiseaseFlowersPlaceboGastroenterologyDiabetes Complicationschemistry.chemical_compoundDouble-Blind MethodInterquartile rangeInternal medicineDiabetes mellitusDrug DiscoverymedicineHumansAgedPharmacologyCrataegusmedicine.diagnostic_testbiologybusiness.industryCholesterolPlant ExtractsC-reactive proteinCholesterol LDLMiddle Agedbiology.organism_classificationmedicine.diseaseSurgeryCrataegus laevigataPlant LeavesC-Reactive ProteinComplementary and alternative medicinechemistryDiabetes Mellitus Type 2biology.proteinMolecular MedicineLipid PeroxidationLipid profilebusinessLeukocyte ElastasePhytotherapyPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

Experiences of a poison center with metformin-associated lactic acidosis.

2004

Metformin is widely used in the treatment of type 2 diabetes, though it is recognized to be associated with the risk of lactic acidosis. A case of pronounced lactic acidosis with cardiac arrest (pH 6.60, lactate 17.5 mmol/l, base excess - 30, standard bicarbonate 2.5 mmol/l, core body temperature 27.8 degrees C) is presented in a 61-year-old woman under metformin therapy. The key laboratory abnormalities observed during the intensive care treatment including repeated hemodialysis are described. The patient showed a complete recovery with residually reduced mental capabilities. Furthermore, an explorative data analysis of our poison center database from 1995 until 2003 concerning metformin w…

medicine.medical_specialtyPoison Control Centersendocrine system diseasesEndocrinology Diabetes and MetabolismPoison controlSuicide AttemptedType 2 diabetesGastroenterologyEndocrinologyInternal medicineInternal MedicinemedicineHumansHypoglycemic AgentsAcidosisbusiness.industryMetabolic disordernutritional and metabolic diseasesMetabolic acidosisGeneral MedicineMiddle Agedmedicine.diseaseMetforminSurgeryMetforminDiabetes Mellitus Type 2Lactic acidosisBase excessAcidosis LacticFemalemedicine.symptombusinessmedicine.drugExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct

A novel component of the metabolic syndrome: The oxidative stress

2009

The metabolic syndrome (MS) represents a cluster of cardiovascular (CV) risk factors associated to CV disease and type 2 diabetes. It is still under debate whether MS is a mere aggregation of risk factors or it represents a clinical entity with visceral obesity as underlying pathophysiological trigger. The publication of several diagnostic criteria of MS by scientific associations or experts panels reflects this uncertainty in understanding the real nature of MS. Besides the metabolic disturbances of MS, as visceral obesity, hypertriglyceridemia, low HDL cholesterol, hypertension and hyperglycemia, novel mechanisms of arterial damage have been identified. This paper reviews the evidence sho…

medicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismMedicine (miscellaneous)Blood lipidsType 2 diabetesDiseaseBiologyBioinformaticsmedicine.disease_causeRisk FactorsInternal medicineDiabetes mellitusmedicineAnimalsHumansDyslipidemiasInflammationMetabolic SyndromeNutrition and DieteticsHypertriglyceridemiaCardiovascular riskmedicine.diseaseObesityOxidative StressEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesObesity AbdominalHypertensionMetabolic syndromeCardiology and Cardiovascular MedicineOxidative stressNutrition, Metabolism and Cardiovascular Diseases
researchProduct

Impact of chronic diuretic treatment on glucose homeostasis

2013

Background The use of diuretics for hypertension has been associated with unfavorable changes in cardiovascular risk factors, such as uric acid and glucose tolerance, though the findings in the literature are contradictory. Methods This study investigated whether diuretic use is associated with markers of metabolic and cardiovascular risk, such as insulin-resistance and uric acid, in a cohort of adults without known diabetes and/or atherosclerotic cardiovascular disease. Nine hundred sixty-nine randomly selected participants answered a questionnaire on clinical history and dietary habits. Laboratory blood measurements were obtained in 507 participants. Results Previously undiagnosed type 2 …

medicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and Metabolismmedicine.medical_treatmentSettore MED/50 - Scienze Tecniche Mediche ApplicateType 2 diabetesGastroenterologySettore MED/13 - Endocrinologiachemistry.chemical_compoundInsulin resistanceDiabetes mellitusInternal medicineInternal MedicinemedicineGlucose homeostasisSettore MED/49 - Scienze Tecniche Dietetiche ApplicateDiureticsbusiness.industryResearchInsulin resistanceType 2 diabetesmedicine.diseaseDiuretics Hypertension Insulin resistance Type 2 diabetes Uric acidEndocrinologychemistryHypertensionCohortUric acidDiureticbusinessUric acidBody mass index
researchProduct

Cerebriform sebaceous nevus: a subtype of organoid nevus due to specific postzygotic FGFR2 mutations.

2021

Background Postzygotic mutations in FGFR2 have been identified in mosaic forms of acne, keratinocytic epidermal nevi, nevoid acanthosis nigricans / rounded and velvety epidermal nevus and in two fetuses with papillomatous pedunculated sebaceous nevus (PPSN). Objectives To determine the clinical and genetic characteristics of children with cerebriform, papillomatous, and pedunculated variants of sebaceous nevi. Methods Infants diagnosed with sebaceous nevi characterized by a cerebriform, papillomatous, and/or pedunculated morphology over a 10-year period (2010 - 2019) at three pediatric dermatology centers in Switzerland and France were included in this case series. Clinical and histological…

medicine.medical_specialtySkin NeoplasmsCutis gyrataDermatologyEpidermal nevusmedicine.disease_causeGermline030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineNevusHumansPediatric dermatologyReceptor Fibroblast Growth Factor Type 2skin and connective tissue diseasesAcanthosis nigricansNevusMutationintegumentary systembusiness.industryOrganoid Nevusmedicine.diseaseDermatologyOrganoidsInfectious Diseases030220 oncology & carcinogenesisMutationbusinessJournal of the European Academy of Dermatology and Venereology : JEADVReferences
researchProduct

Growth and differentiation factor 11 (GDF11): Functions in the regulation of erythropoiesis and cardiac regeneration

2015

International audience; Members of the TGF-β superfamily transduce their signals through type I and II receptor serine/threonine kinases. The binding of activins to activin type IIA (ActRIIA) or type IIB (ActRIIB) receptors induces the recruitment and phosphorylation of an activin type I receptor (ALK4 and/or ALK7), which then phosphorylates the Smad2 and Smad3 intracellular signaling proteins. The regulation of members of the TGF-β family is known to be complex, because many proteins able to bind the ligands and inhibit their activities have been identified. Growth and differentiation factor 11 (Gdf11) belongs to the TGF-β family. GDF11, like other members of the TGF-β superfamily, is prod…

medicine.medical_specialtySmad2 ProteinProtein Serine-Threonine Kinases030204 cardiovascular system & hematologyBiology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineTGF beta signaling pathway[SDV.BBM] Life Sciences [q-bio]/Biochemistry Molecular BiologymedicineHumansRegeneration[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologyPharmacology (medical)PhosphorylationCCL11Activin type 2 receptors030304 developmental biologyPharmacology0303 health sciencesR-SMADcardiac regenerationGrowth differentiation factorHeartActivins[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemCell biologyBMPR2Growth Differentiation FactorsEndocrinologyBone Morphogenetic ProteinsGDF11Smad2 ProteinSignal transductionActivin Receptors Type IerythropoiesisACVR2BSignal TransductionPharmacology &amp; Therapeutics
researchProduct

Liraglutide reduces plasma PCSK9 in patients with type 2 diabetes not treated with statins

2022

Dyslipidaemia in type 2 diabetes mellitus (T2DM), which increases cardiovascular risk, includes abnormal metabolism of low-density lipoproteins (LDL). Our group has recently shown that liraglutide increases LDL catabolism in patients with T2DM and that it reduces the expression of PCSK9 (a major inhibitor of LDL-receptor expression) in vitro and in mice. This prompted us to study the effect of liraglutide on plasma PCSK9 level in patients with T2DM.We studied prospectively 82 patients with T2DM (51 without statins, 31 with statins). Plasma PCSK9 and plasma lipids were measured before and six months after the initiation of a treatment with liraglutide at a dose of 1.2 mg/day.Plasma PCSK9 was…

medicine.medical_specialtyStatinendocrine system diseasesmedicine.drug_classEndocrinology Diabetes and MetabolismType 2 diabetesMiceEndocrinologyDiabetes mellitusInternal medicineInternal MedicinemedicineAnimalsHumansGlycated HemoglobinCatabolismbusiness.industryLiraglutidePCSK9nutritional and metabolic diseasesType 2 Diabetes MellitusGeneral MedicineMetabolismLiraglutidemedicine.diseaseEndocrinologyDiabetes Mellitus Type 2lipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsProprotein Convertase 9businessmedicine.drugDiabetes &amp; Metabolism
researchProduct

GLP-1 receptor agonists in NAFLD.

2017

IF 4.101; International audience; Non-alcoholic fatty liver disease (NAFLD) is very common in patients with type 2 diabetes (T2D), with approximately two-thirds having a diagnosis of the disease. Currently, the only validated treatment for NAFLD is weight loss. A number of studies of animal models and human trials have evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on liver fat content and suggest that the treatment could represent a new alternative for NAFLD management. In this review, our focus is on the main studies regarding the effects of GLP-1RAs on NAFLD. Also, the mechanisms that might explain their beneficial effects on liver diseases are analyzed.

medicine.medical_specialtySteatosisEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismDiseaseType 2 diabetesGastroenterologyGlucagon-Like Peptide-1 Receptor03 medical and health sciences0302 clinical medicineEndocrinologyFibrosisWeight lossInternal medicineInternal MedicineHumansHypoglycemic AgentsMedicineReceptorGlucagon-like peptide 1 receptorGLP-1 receptor agonistsbusiness.industryFatty livernutritional and metabolic diseasesGeneral Medicine[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseFibrosisdigestive system diseasesTreatment OutcomeDiabetes Mellitus Type 2030211 gastroenterology & hepatologytype 2 diabetesSteatosismedicine.symptombusinessNon-alcoholic fatty liver disease
researchProduct

Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis.

2014

Aims Insulin resistance (IR) is a major risk factor for cardiovascular disease and atherosclerosis. Life-threatening acute events are mainly due to rupture of unstable plaques, and the role of vascular smooth muscle cells (VSMCs) in this process in IR, Type 2 diabetes mellitus, and metabolic syndrome (T2DM/MetS) has not been fully addressed. Therefore, the role of VSMC survival in the generation of unstable plaques in T2DM/MetS and the involvement of inflammatory mediators was investigated. Methods and results Defective insulin receptor substrate 2 (IRS2)-mediated signalling produced insulin-resistant VSMCs with reduced survival, migration, and higher apoptosis than control cells. Silencing…

medicine.medical_specialtyVascular smooth musclePhysiologyCell Survivalmedicine.medical_treatmentMyocytes Smooth MuscleCX3C Chemokine Receptor 1InflammationMice TransgenicBiologyMuscle Smooth VascularInsulin resistanceApolipoproteins EPhysiology (medical)Internal medicinemedicineAnimalsHumansProtein kinase BPI3K/AKT/mTOR pathwayCells CulturedMice KnockoutChemokine CX3CL1Insulinmedicine.diseaseAtherosclerosisIRS2Mice Inbred C57BLAtheromaEndocrinologyDiabetes Mellitus Type 2cardiovascular systemReceptors Chemokinemedicine.symptomInsulin ResistanceCardiology and Cardiovascular MedicineSignal TransductionCardiovascular research
researchProduct